All In Biotech

Drug Trial Radar · NCT05669014

A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Daxdilimab Subcutaneous Injection in Adult Participants With Inadequately Controlled Dermatomyositis or Anti-synthetase Inflammatory Myositis.

Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

12

Actual

Start

Dec 4, 2023

Primary completion

Jul 2, 2025

Study completion Jul 2, 2025

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Dec 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary efficacy objective: To evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24. The secondary efficacy objectives include: 1. To evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24. 2. To evaluate the effect of daxdilimab compared with placebo on skin symptoms at Week 24. 3. To evaluate the effect of daxdilimab on decreasing the use of corticosteroid at Week 24. Other secondary objectives include: 1. To characterize the pharmacokinetics (PK) and immunogenicity of daxdilimab in participants. 2. To evaluate the safety and tolerability of daxdilimab in participants.

Conditions

  • Idiopathic Inflammatory Myositis

Interventions

  • DaxdilimabDrug

    Participants will be administered daxdilimab by subcutaneous (SC) injection.

  • PlaceboDrug

    Participants will be administered identically matching placebo by SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Total Improvement Score (TIS) at Week 24Time frame: At Week 24

Locations

9 sites in 6 countries. Site status is shown where the registry gives one.

  • Advanced Research Center, Inc.

    Anaheim, California

  • Centro Mineiro de Pesquisa - CMiP

    Juiz de Fora, Minas Gerais, Brazil

  • LMK Servicos Medicos SS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Revmatologicky ustav

    Prague, Praha, Hlavní Mesto, Czechia

  • Unidad de Investigacion de las Enfermedades Reumaticas S.A. De C.V.

    Mexico City, Mexico

  • Accelerium, S. de R.L. de C.V. - PPDS

    Monterrey, Mexico

  • Hospital Quironsalud Infanta Luisa

    Seville, Spain

  • Aintree University Hospital - NWCRN - PPDS

    Liverpool, Merseyside, United Kingdom

  • Western General Hospital Edinburgh - PPDS

    Edinburgh, Midlothian, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.